Axsome Therapeutics (MEX:AZSM) Total Inventories: MXN568 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:AZSM Axsome Therapeutics Inc MEX:AZSM
52 GF Score
Price MXN1,519.00
GF Value MXN1,494.25
! 1 Warning Sign
View Full Analysis

What is Axsome Therapeutics Total Inventories?

Axsome Therapeutics MEX:AZSM 52 Total Inventories is MXN568 Mil as of Mar. 2026. GuruFocus rates MEX:AZSM with a GF Score™ of 52/100 and a GF Value™ of MXN1,494.25. The stock has 1 warning sign investors should review.

Axsome Therapeutics's total inventories for the quarter that ended in Mar. 2026 was MXN568 Mil. Axsome Therapeutics's average total inventories from the quarter that ended in Dec. 2025 to the quarter that ended in Mar. 2026 was MXN536 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Axsome Therapeutics's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was MXN-52.56.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Axsome Therapeutics's Days Inventory for the three months ended in Mar. 2026 was 184.08.

Inventory Turnover measures how fast the company turns over its inventory within a year. Axsome Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.50.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Axsome Therapeutics's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.16.

Axsome Therapeutics  (MEX:AZSM) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Axsome Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is

Net-Net Working Capital Per Share (Q: Mar. 2026 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(5501.885+0.75 * 4527.326+0.5 * 568.301-11883.91
-0-0)/51.420
=-52.56

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Axsome Therapeutics's Days Inventory for the three months ended in Mar. 2026 is calculated as:

Days Inventory=Average Total Inventories (Q: Mar. 2026 )/Cost of Goods Sold (Q: Mar. 2026 )*Days in Period
=535.672/265.531*365 / 4
=184.08

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Axsome Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2026 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Mar. 2026 ) / Average Total Inventories (Q: Mar. 2026 )
=265.531 / 535.672
=0.50

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Axsome Therapeutics's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=535.672 / 3447.906
=0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Axsome Therapeutics Total Inventories Related Terms

Axsome Therapeutics Total Inventories Historical Data

* Premium members only.

The historical data trend for Axsome Therapeutics's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Axsome Therapeutics Total Inventories Chart

Axsome Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Inventories
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 84.22 256.91 328.10 503.04

Axsome Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 333.86 347.23 436.12 503.04 568.30
MEX:AZSM
52GF Score
Axsome Therapeutics Inc MEX:AZSM
Total Inventories is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Axsome Therapeutics Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Frequently Asked Questions Learn more about Total Inventories →
What does a Total Inventories of MXN568 Mil mean?
Axsome Therapeutics (MEX:AZSM) has a Total Inventories of MXN568 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Axsome Therapeutics and its competitors.
Is Axsome Therapeutics' Total Inventories too high?
Axsome Therapeutics' current Total Inventories is MXN568 Mil. Overall, Axsome Therapeutics has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Axsome Therapeutics' Total Inventories compare to MDGL and IONS?
Axsome Therapeutics' Total Inventories of MXN568 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Axsome Therapeutics and its competitors. Axsome Therapeutics's current Total Inventories is MXN568 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Axsome Therapeutics stock overvalued right now?
Axsome Therapeutics (MEX:AZSM) has a current Total Inventories of MXN568 Mil. The stock's GF Value™ is MXN1,494.25, compared to a current price of MXN1,519.00 — trading 1.7% above its estimated fair value. The current Total Inventories is MXN568 Mil. Axsome Therapeutics' overall GF Score™ is 52/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Axsome Therapeutics (MEX:AZSM), the current Total Inventories is MXN568 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Axsome Therapeutics (MEX:AZSM) Overvalued in 2026?

Based on GuruFocus' analysis, Axsome Therapeutics stock appears to be overvalued. The current stock price of MXN1,519.00 is trading 1.7% above its estimated GF Value™ of MXN1,494.25.

Key valuation signals for MEX:AZSM:

  • Total Inventories: MXN568 Mil
  • GF Value™: MXN1,494.25 vs. price of MXN1,519.00 (1.7% above fair value)
  • GF Score™: 52/100 with 1 warning sign

No single metric tells the full story. See the MEX:AZSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Axsome Therapeutics Business Description

Address One World Trade Center, 29th Floor, New York, NY, USA, 10007
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
52GF Score

Get the complete analysis for MEX:AZSM

Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,519.00
Price
MXN1,494.25
GF Value